Tumor necrosis factor-alpha plays an important role in restenosis development

Area of Science:

• Cardiovascular Research
• Genetics
• Inflammation Biology

Background:

• Restenosis after percutaneous coronary intervention (PCI) is influenced by genetic factors and inflammation.
• Tumor necrosis factor-alpha (TNFalpha), a key inflammatory mediator, is implicated in restenosis development.
• The GENetic DEterminants of Restenosis (GENDER) project investigates genetic influences on restenosis.

Purpose of the Study:

• To evaluate the role of TNFalpha gene polymorphisms in restenosis risk after PCI.
• To assess the impact of TNFalpha on restenosis in preclinical models.
• To explore TNFalpha as a potential therapeutic target for restenosis.

Main Methods:

• Systematic genotyping of six TNFalpha gene polymorphisms in 3104 PCI patients.
• Assessment of TNFalpha's role in ApoE*3-Leiden and TNFalpha knockout mice models.
• Evaluation of thalidomide, a TNFalpha biosynthesis inhibitor, in a mouse restenosis model.

Main Results:

• The -238G-1031T TNFalpha haplotype was associated with increased clinical and angiographic restenosis risk (P=0.02 and P=0.002).
• Arterial TNFalpha mRNA levels were significantly upregulated over time in a mouse model of reactive stenosis.
• Mice lacking TNFalpha or treated with thalidomide exhibited reduced reactive stenosis (P=0.01 and P=0.005).

Conclusions:

• Clinical and preclinical evidence confirms TNFalpha's significant role in restenosis.
• TNFalpha genotype may serve as a valuable risk marker for predicting restenosis post-PCI.
• Inhibition of TNFalpha presents a promising anti-restenotic therapeutic strategy.